Clara cell protein (CC16) is a well-known anti-inflammatory protein secreted by the epithelial Clara cells of the airways. It is involved in the development of airway inflammatory diseases such as chronic obstructive pulmonary disease and asthma. Previous studies suggest that CC16 gene transfer suppresses expression of interleukin (IL)-8 in bronchial epithelial cells. However, its role in the function of these cells during inflammation is not well understood. In this study, we evaluated the effect of CC16 on the expression of matrix metalloproteinase (MMP)-9 in lipopolysaccharide (LPS)-stimulated rat tracheal epithelial cells and its underlying molecular mechanisms. We generated recombinant rat CC16 protein (rCC16) which was bioactive in inhibiting the activity of phospholipase A 2 . rCC16 inhibited LPS-induced MMP-9 expression at both mRNA and protein levels in a concentration-dependent (0-2 mg/mL) manner, as demonstrated by real time RT-PCR, ELISA, and zymography assays. Gene transcription and DNA binding studies demonstrated that rCC16 suppressed LPS-induced NF-kB activation and its binding of gene promoters as identified by luciferase reporter and gel mobility shift assays, respectively. Western blotting and immunofluorescence staining analyses further revealed that rCC16 concentration dependently inhibited the effects of LPS on nuclear increase and cytosol reduction of NF-kB, on the phosphorylation and reduction of NF-kB inhibitory IkBa, and on p38 MAPK-dependent NF-kB activation by phosphorylation at Ser276 of its p65 subunit. These data indicate that inhibition of LPS-mediated NF-kB activation by rCC16 involves both translocation-and phosphorylation-dependent signaling pathways. When the tracheal epithelial cells were pretreated with chlorpromazine, an inhibitor of clathrin-mediated endocytosis, cellular uptake of rCC16 and its inhibition of LPS-induced NF-kB nuclear translocation and also MMP-9 production were significantly abolished. Taken together, our data suggest that clathrin-mediated uptake of rCC16 suppresses LPS-mediated inflammatory MMP-9 production through inactivation of NF-kB and p38 MAPK pathways in tracheal epithelial cells.
Introduction
Clara cell protein (CC16), also known as UP1, UG, PCB-BP, or CC10, is a 16-kDa homodimeric protein secreted predominantly by non-ciliated airway epithelial (Clara) cells and is regarded as an anti-inflammatory factor native to the lung. [1] [2] [3] In the lungs, CC16 suppresses the release of proinflammatory cytokines, such as TNF-a, IL-1b, and IFN-g. 4 Reduced levels of CC16 in bronchial epithelium or sputum supernatants of chronic obstructive pulmonary disease (COPD) patients and reduction of CC16-positive epithelial cells in small airways of asthmatics both contribute to aggravation of inflammatory responses in chronic lung inflammation. [5] [6] [7] Gene knockout studies show that mice which lack CC16 develop increased susceptibility and exaggerated inflammatory responses to the exposure of hyperoxic and infectious agents. 8 These results indicate that CC16 is important in maintaining lung homeostasis.
In lung inflammation diseases, lung structures are mainly damaged by excessive proteinase activity, such as matrix metalloproteinase 9 (MMP-9). 9 MMP-9 is the largest and most structurally complex member of the MMPs which degrade extracellular matrix and cellular junctions during inflammatory cell recruitment. [10] [11] [12] Increased levels of MMP-9 have been found in the sputum and lavage samples of patients during COPD and asthma exacerbation. 13, 14 Elevated MMP-9 expression in the lung diseases is also associated with activation of nuclear factor kappa B (NF-kB), 15, 16 which is a principal transcription factor involved in the process of airway inflammation. 17 Therefore, a combination of CC16 deficiency in chronic lung inflammation, together with advancing lung damages due to increase in MMP-9, suggests that CC16 mediates MMP-9 expression and contributes to lung homeostasis.
The aim of this study was to test the hypothesis that CC16 suppresses inflammatory response by reducing MMP-9 expression through NF-kB signaling pathways. We generated recombinant rat CC16 (rCC16) to treat rat tracheal epithelial cells (RTE) and monitored the inflammatory responses (i.e. MMP-9 expression and NF-kB activation) induced by subsequent LPS incubation. 18, 19 MMP-9 expression was determined by real time RT-PCR, ELISA, and its potential activity using zymography assays. NF-kB activation was followed by luciferase reporter, electrophoretic mobility shift assay (EMSA) and Western blotting techniques, and NF-kB binding of gene promoters by gel mobility shift assays. We also explored the cellular entry pathway of rCC16 by clathrin-mediated endocytosis. Our results suggest that administration of rCC16 reduces LPS-induced MMP-9 expression and activation of NF-kB pathways in RTE cells.
Materials and methods
Expression and purification of recombinant rCC16 protein rCC16 was expressed and purified as described previously. 20 Briefly, the open reading frame (ORF) of rat CC16 gene (GeneBank Accession Number: NM_013051) was amplified from rat lung cDNA library (provided by Min Guo, Shanxi Medical University) and cloned into the pET-30a (þ) vector (Novagen, Germany). His-tagged rCC16 was induced to express in Escherichia coli Rosetta (DE3) cells with 0.1 mM isopropy-b-D-thiogalactoside (IPTG) at 23 C and purified via Ni 2þ -NTA agarose (Qiagen, Germany) by elution with 150 mM imidazole at 4 C. The endotoxin contents in the protein preparations were determined and removed by using a chromogenic end-point endotoxin assay Kit and a ToxinEraser TM endotoxin removal kit according to the manufacturer's instructions (Horseshoe Crab Reagent Manufactory, Xiamen, China). Less than 0.1 EU/mL of endotoxin was detected in the final purified proteins. Purity of rCC16 was analyzed using a Ä KtA avant 25 high-performance liquid chromatography (HPLC) system (Zorbax SB-C18, Agilant, USA) according to previous protocols, 21, 22 and protein contents were monitored by UV detection at 280 nm/254 nm/214 nm. Over 95% purity, rCC16 was quantified using Bicinchoninic Acid assay Protein Reagent kit (CWBIO, Beijing, China), dialyzed against PBS, filtered through a 0.2 mm pore membrane, and stored at -70 C until use.
Cell culture and drug treatments
The rat tracheal epithelial (RTE) cell line was purchased from the Cell Culture Center of the Chinese Academy of Medical Sciences (Beijing, China) and cultured in Minimal Essential Medium with Earle's Salts (MEM-EBSS, Life Technologies) supplemented with 20% fetal calf serum (HyClone; Thermo Scientific), 100 U/mL penicillin, and 100 mg/mL streptomycin in a 5% CO 2 humidified atmosphere at 37 C. A549 cells were kindly provided by Dr Junbo Liang (National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Peking Union Medical College, Tsinghua University) and cultured in Dulbecco's Modified Eagle Medium (Life Technologies) supplemented with 10% fetal calf serum. Adherent cells were passaged every 3-4 days with 0.25% trypsin-EDTA (Life Technologies).
Cell Counting Kit-8 (CCK-8, Dojindo, Japan) and Trypan Blue (Fluka, USA) exclusion methods were used for cell viability assays. RTE cells were seeded in 96-well plates at 1 Â 10 4 cells/well in triplicate and cultured with rCC16 at 5, 10, 20 mg/mL or PBS controls for one, three, five, or seven days. The cells were then incubated with 100 mL of fresh medium containing 10 mL CCK-8 reagent at 37 C for 3 h, and colorimetric CCK-8 reduction by live cells was measured at 450 nm with an ELISA plate reader. For Trypan Blue exclusion assay, RTE cells were seeded at 1 Â 10 5 cells/well in 24-well plates in triplicate and treated as earlier. After trypsinization, the cells were stained with Trypan Blue (0.4%), and the number of viable (non-stained) and dead (stained) cells was determined using a hemocytometer under a phase-contrast microscopy.
For drug treatment, subconfluent cultures of RTE cells were washed with PBS, incubated with rCC16 at 0.5, 1.0, or 2.0 mg/mL in serum-free media for 2 h prior to LPS (0.1 mg/ mL) application, and were maintained for further 1, 24 h. For NF-kB pathway analysis, pyrrolidine dithiocarbamate (PDTC, Sigma-Aldrich) was added to the RTE cells in complete media at 50 mM 2 h prior to the LPS treatment in serum-free media for further 24 h. Cell culture supernatants or cells were then harvested for subsequent analysis as described below.
Phospholipase A 2 (PLA 2 ) activity assay
The activity of PLA 2 was measured using lecithin as a substrate by acid-base titrations according to previous protocols 23, 24 with minor modifications. In the presence of Ca 2þ , lecithin is hydrolyzed by PLA 2 into titratable fatty acids. Briefly, the reaction was performed at 37 C for 60 min in 10 mL of a reaction medium containing 1.2 nM PLA 2 , 10 mM CaCl 2 , 3 mM lecithin (Sigma) substrate solution (incl. 80 mM glycine, 3 mM boric acid, 4.8 mM sodium deoxycholate, pH 8.50) in presence or absence of rCC16 at various concentrations. The reaction was terminated by adding EDTA at 1.5 mM to the testing tubes, and the same amount of EDTA was included in the reference tubes (containing the same concentration of rCC16) in the absence of CaCl 2 before the incubation. The pH in the reference tubes was determined to the equivalent of their testing tubes with a Starter 2100 pH meter (Ohaus, USA) using 2 mM HCI as titrant. In each experiment, controls were included which were not exposed to rCC16. PLA 2 activity was quantified in absolute units by the consumption of nanomoles of HCI per min required to match the fatty acids produced in the testing, and results were expressed as % of tests relative to controls without rCC16.
RT-PCR
After treatment with rCC16 and LPS, cells were harvested and total RNA was extracted using Trizol reagent (CWBIO, Beijing, China). The concentration and purity of RNA were quantified by ultraviolet absorbance at 260 and 280 nm. Real-time RT-PCR was performed with the Applied Biosystems Õ Real-Time PCR Instruments using an UltraSYBR Two Step RT-qPCR Kit (CWBIO, Beijing, China) according to the manufacturer's instructions. Reverse transcription was performed for 50 min at 42 C with 1 mg total RNA. PCR was carried out in a 20 mL reaction mixture containing 1 mL cDNA template under conditions: denaturing at 95 C for 1 min, 40 cycle amplification at 95 C for 10 s and 60 C for 40 s in triplicates. The 2 ÀÁÁCT method was used to calculate the relative levels of gene expression, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression was used as internal control. The sequences of primers used for the real-time PCR were: MMP-9 (sense 5 0 -TATCACTACCACGAGGACTCCC-3 0 , antisense 5 0 -TCAGGTT TAGAGCCACGACC-3 0 ) and GAPDH (sense 5 0 -GTGCCAGCCTCGTCTCATAG -3 0 , antisense 5 0 -CTTTGTCACAAGAGAAGGCAG-3 0 ). To detect endogenous CC16 mRNA expression in RTE cells, total RNA was extracted from RTE cells using Trizol reagent, cDNA was synthesized, and CC16 was amplified according to the published protocols. 20 GAPDH was used as an internal control with the primers: sense 5 0 -ACCACAGTCCATGCCATCAC-3 0 , antisense 5 0 -TCC ACCACCCTGTTG CTGTA-3 0 .
Quantification of MMP-9 protein levels in culture supernatants RTE cells, seeded at 2.5 Â 10 5 cells/well in 12 well plates, were cultured overnight, incubated with or without rCC16 at different concentrations for 2 h, and then followed by LPS stimulation at 0.1 mg/mL in serum-free media for the time as indicated. Culture supernatants were harvested, centrifuged, and used for determining the levels of MMP-9. For assessing the role of endocytosis, cells were treated with 30 mM chlorpromazine (Sigma) or vehicles for 30 min, incubated with or without 2.0 mg/mL rCC16, and then followed by LPS stimulation at 0.1 mg/mL for 24 h. Culture supernatants were harvested, centrifuged, and used for determining the levels of MMP-9 using a rat MMP-9 ELISA development kit (Westang, Shanghai, China) according to the manufacturer's instructions. The sensitivity of this kit was 2.0 ng/mL.
Gelatin zymography analysis of MMP-9
Following the treatments with rCC16 for 2 h and LPS for further 24 h as described earlier, the potential enzyme activities of MMP-9 in the cell culture supernatants were determined with gelatin zymography assay as a measure of its levels of expression. Protein content was determined with the BCA method, and 20 mg proteins were fractionated by 10% SDS-PAGE containing 1 mg/mL gelatin A (Sigma) that serves as the enzyme substrate. After electrophoresis, the gel was soaked to remove SDS in a Triton X-100 solution (zymograming), the proenzyme of MMP-9 in the gel is activated to react with its gelatin substrate. Following staining with 0.5% Coomassie Blue R-250 for 30 min and destaining with 45% methanol, 10% (v/v) acetic acid, the clear bands generated due to MMP-9 activities against a blue background were quantified by densitometry using Tanon 1600 Gel Image Analysis System (Tanon, Shanghai, China).
NF-iB luciferase reporter assay
RTE cells seeded at 1 Â 10 5 cells/well in 24 well plates were cultured overnight and co-transfected at 70-80% confluence with 0.5 mg NF-kB promoter Firefly luciferase reporter and 0.02 mg Renilla luciferase constructs (Beyotime, China) using Lipofectamine 2000 (Life Technologies) according to the manufacturer's protocols. Twenty-four hours after transfection, the cells were exposed to rCC16 at different concentrations for 2 h and then incubated with 0.1 mg/mL LPS for another 24 h. Cell extracts were prepared and the activities of the two reporter enzymes (Firefly and Renilla luciferases) were determined using the Dual-Luciferase Reporter Assay System (Promega) with a luminometer (TD-20/20, Turner BioSystems, USA) as per the manufacturer's instructions. The transcriptional activities of NF-kB were expressed as relative luciferase activities calculated as the ratio of Firefly luciferase activity to Renilla luciferase activity.
Electrophoresis mobility shift assay
Nuclear proteins were extracted from RTE cells treated with rCC16 (1.0 or 2.0 mg/mL, 2 h) and LPS (0.1 mg/mL, 1 h) and incubated with biotin-labeled double stranded oligonucleotide containing the consensus sequence of NF-kB-DNA binding site (59-AGTTGAGGGGACTTTCCCAGG-39) as described. 18 Binding reaction mixtures (20 mL) containing 4 mg nuclear extract protein, 1 mg poly-dI.dC (Thermo Scientific), and 20 ficomoles biotin-labeled probe in binding buffer (10 mM Tris, 50 mM potassium chloride, 1 mM dithiothreitol, 0.1 mM EDTA, 2.5% glycerol, 5 mM magnesium chloride) were incubated for 20 min at room temperature. Cold competition and non-specific binding was performed by adding 200-fold excess of unlabeled probe to the reaction mixtures for 20 min prior to addition of biotinylated probes. DNA-protein complexes were resolved on a 6% non-denaturing polyacrylamide gels and blotted onto a Biodyne B (0.45 mm) positively charged nylon membrane (Thermo Scientific). The retarded bands were detected by chemiluminescence using the LightShift Chemiluminescent EMSA kit according to the manufacturer's instructions (Thermo Scientific).
Western blotting analysis
Total protein extraction was prepared by cell lysing using SDS lysis buffer containing 50 mM Tris-HCl (pH 6.8), 10% glycerol, and 2% SDS. Nuclear proteins were extracted by using a NE-PER Nuclear and Cytoplasmic Extraction kit (Thermo Scientific). The protein samples were quantified using the BCA protein assay reagent, resolved by 12% SDS-PAGE gel electrophoresis and transferred to polyvinylidene fluoride (PVDF) membranes. Membranes were blocked for 1 h at room temperature with 5% skim milk and then incubated overnight at 4 C with the indicated primary antibodies at 1:1000 dilutions unless otherwise indicated: p65, IkBa, Phospho-IkBa (Ser32), p38 MAPK, Phospho-p38 MAPK (Thr180/Tyr182) (Cell Signaling Technology), Phospho-p65 (Ser276), Histone H1, CC16 (Santa Cruz), or b-actin (1:3000, Sigma). Proteins were visualized using an anti-rabbit, antimouse, or anti-goat secondary antibody conjugated to Horseradish Peroxidase (HRP) and a chemiluminescence ECL detection system (Pierce, USA). Band intensities were quantified using a Tanon 1600 Gel Image Analysis System.
Immunofluorescence staining assay
Subconfluent RTE cells grown on glass coverslips were incubated with or without rCC16 at different concentrations for 2 h and then subjected to LPS stimulation at 0.1 mg/mL for another 1 h. The subcellular distributions of NF-kB/p65 were assessed by immunofluorescence staining. To verify the mode of cellular uptake of rCC16, RTE cells grown on coverslips in 12-well plates were exposed to 30 mM chlorpromazine (Sigma) or controls for 30 min at 37 C in serum-free medium. For assays to determine the effect of chlorpromazine on rCC16 activities, the RTE cells treated with chlorpromazine and rCC16 were subjected to incubations with LPS at 0.1 mg/mL for another 1 h. The culture medium was replaced with growth medium containing 2.0 mg/mL rCC16 and incubated for another 30 min. The subcellular locations of His-rCC16 were analyzed via immunofluorescence staining. To detect CC16 expression in RTE cells, subconfluent RTE cells and A549 cells (which expresses CC16 25 and serves as a positive control) were cultured on glass coverslips for 24 h. The cells were fixed with 4% paraformaldehyde in PBS for 20 min at RT, blocked with 3% bovine serum albumin in PBS, and incubated overnight at 4 C with a rabbit anti-p65 antibody (1:100, Cell Signaling Technology) or a mouse anti-His monoclonal antibody (1:100, Cell Signaling Technology) for the detection of His-tagged rCC16 using a mouse IgG isotype as negative controls. A goat anti-CC16 polyclonal antibody (1:50) was used for the detection of endogenous CC16 with a goat IgG isotype as negative controls. Following washes with PBS, cells were stained with an Alexa Fluor 488-conjugated goat anti-rabbit antibody (1:200), Alexa Fluor 546-conjugated goat anti-mouse antibody (1:400), or Alexa Fluor 546 donkey anti-goat antibody (1:400) (Life Technologies) and nuclei staining with DAPI (Sigma) in PBS for 1 h at RT. Cells were visualized and imaged under a fluorescence microscope (Olympus, CKX41-F32FL).
Statistical analysis
All data are presented as mean AE SD for three or more independent experiments. Multiple group comparisons were performed with one-way analysis of variance, and comparisons between two groups were performed by the Student's t-test by using the Prism software (Version 5, GraphPad). Differences were considered statistically significant at a P value less than 0.05.
Results rCC16 inhibits the activity of PLA 2
In order to assess the role of rCC16 in suppression of LPSinduced inflammatory responses, we first generated rCC16 and determined its bioactivity and concentration range of cytotoxicity. His-tagged rCC16 was expressed in E. coli cells and purified via Ni 2þ gel column, the purity was over 95% as detected by SDS-PAGE with Coomassie blue R250 staining 20 and by high performance liquid chromatography (HPLC) as shown in supplemental Figure 1 . For all other experiments, we employed the RTE cell line in which CC16 expression is absent or at very low levels as determined by RT-PCR, Western blotting, and immunofluorescence staining assays (supplemental Figure 2 ). To evaluate the biological activity of rCC16, we initially determined the effect of rCC16 on PLA 2 activity since endogenous CC16 protein inhibits PLA 2 activity. 26, 27 Figure 1 (a) shows that rCC16 inhibited PLA 2 activity in a concentration-dependent manner. After 1 h treatment, significant PLA 2 inhibition was observed at 0.5 mg/mL rCC16 (P<0.05) and reached higher level at 1.0 and 2.0 mg/mL rCC16 (P<0.01).
To analyze the cytotoxic effect of rCC16 on its applications, RTE cells were treated with rCC16 at 5, 10, 20 mg/mL or PBS control, and cell viability was assessed one, three, five, and seven days later. As shown in Figure 1(b) , exposure of RTE cells to rCC16 evoked both concentration-and time-dependent inhibition of cell proliferation compared to PBS controls, as determined by CCK-8 assays. While significant cell proliferations were observed in PBS controls and cells treated with 5 mg/mL rCC16 for seven days, significant reductions of cell numbers were also observed at 10 and 20 mg/mL after five days exposure to rCC16 and reached higher level at day 7 (P < 0.01). To further verify that the cell number reduction seen at high concentrations of rCC16 over five days is due to reduced cell proliferation, we performed trypan blue staining of the cells and counted the living and dead cells under phase contrast microscopy. Indeed, no difference of cell viability was observed in cells treated with different concentrations of rCC16 over the seven days (Figure 1(c) ). These data indicated that the rCC16 we produced was biologically active and displayed no cytotoxic effect at low concentrations (5 mg/mL or lower).
rCC16 inhibits LPS-induced MMP-9 expression in RTE cells
LPS is a major component of the outer membrane of gramnegative bacteria and commonly used to study inflammation. 28 To evoke inflammatory responses in the RTE cells, we used LPS at a concentration of 0.1 mg/mL which was previously shown to induce MMP9 mRNA expression through the NF-kB pathway in A549 lung epithelial cells. 29 A role of MMP-9 in the development of inflammation is also well established as an inflammatory marker. 30, 31 To determine whether rCC16 plays an anti-inflammation role in airway epithelial cells, we therefore investigated the effect of rCC16 on LPS-induced MMP-9 expression in RTE cells by real-time PCR and ELISA assays. RTE cells were pretreated with rCC16 at 0.5, 1.0, and 2.0 mg/mL for 2 h prior to the addition of 0.1 mg/mL LPS for further 24 h. As shown in Figure 2 , increased expression of MMP-9 was observed on both mRNA (Figure 2(a) ) and protein levels (Figure 2(b) ) in LPS-treated RTE cells, and these LPS-stimulated MMP-9 expressions were inhibited by rCC16 in a dose-dependent manner, being significant at concentrations over 1.0 mg/mL. In accord, a similar concentration-dependent reduction of MMP-9 activities in the culture media of rCC16-treated RTE cells was revealed by zymography assays (Figure 2(c) and (d) ). These results suggest that rCC16 inhibits LPS-induced MMP-9 expression and its activities.
rCC16 suppresses the transcriptional activity and DNA binding of NF-iB NF-kB activation is critical to LPS-induced transcriptional regulation of inflammation 32 and MMP-9 activities in airway inflammation. 16 To determine whether the NF-kB pathway is required for MMP9 expression in the RTE cells we employed here, the specific NF-kB inhibitor PDTC (50 mM) was applied to the cells for 2 h prior to LPS treatment. The results showed that PDTC significantly inhibited LPS-evoked MMP9 protein expression (supplemental Figure 3 ), as previously determined under similar conditions in the lung epithelial cells. 29 We next performed dual luciferase reporter assays to assess whether suppression of MMP-9 by rCC16 in LPS-stimulated RTE cells is dependent on NF-kB-mediated transcriptional activation. As shown in Figure 3 (a), LPS caused an approximate ninefold increase in relative luciferase activity, and rCC16 inhibited LPS-induced NF-kB transcriptional activity in a concentration-dependent manner, from 38.8% at 1.0 mg/ mL to 62.6% reduction at 2.0 mg/mL. To further verify the inhibitory effect of rCC16 on NF-kB activity, EMSA were employed to determine whether rCC16 could inhibit DNA binding activity of NF-kB using a biotin-labeled consensus p65 probe of NF-kB. As shown in Figure 3 (b), LPS treatment augmented the DNA binding activity significantly, and rCC16 suppressed LPS-induced NF-kB-DNA binding at 1.0 and 2.0 mg/mL in a concentration-dependent manner. These findings indicate that rCC16 suppresses the transcriptional activity of NF-kB by blocking its DNA bindings.
rCC16 suppresses NF-iB nuclear translocation
In resting cells, NF-kB is sequestered in the cytosol by its inhibitor IkB. Once it is stimulated by LPS, IkBa is phosphorylated and rapidly degraded via proteasome pathway, leading to the release of NF-kB and its translocation to the nucleus. 30, 33 We therefore performed Western blotting analysis to assess the effect of rCC16 on the cytoplasmic and nuclear distribution of the NF-kB proteins upon LPS stimulation. As shown in Figure 4(a) , an increased level of NF-kB/p65 in the nucleus was seen in LPS-treated cells, and this nuclear increase of NF-kB/p65 protein was significantly suppressed by rCC16 at 1.0 and 2.0 mg/mL but not 0.5 mg/mL. Being consistent, decreased level of cytosol NF-kB/p65 was observed in LPS-treated cells, and rCC16 rescued this decrease at similar concentrations (Figure 4(b) ) without affecting the total cellular levels of NF-kB/p65 (Figure 4(c) ). To further confirm the effect of CC16 on the relocation of NF-kB in LPS-treated RTE, we performed immunofluorescence staining of NF-kB. Distribution of NF-kB/p65 was found in the nucleus in LPS-treated cells, and it was significantly repressed by rCC16 at concentrations 1.0 and 2.0 mg/mL but not 0.5 mg/mL (Figure 4(d) ). These data suggest that rCC16 inhibition of NF-kB transcriptional activity also involves blockage of LPS-induced nuclear translocation of its p65 subunit in the RTE cells. 
rCC16 prevents the phosphorylation of IiBa
As mentioned earlier, NF-kB activity is regulated by cytoplasmic phosphorylation and degradation of its inhibitory unit IkB, and translocation of its p65 subunit to the nucleus. 30, 34 To determine whether rCC16 inhibition of NF-kB nuclear translocation also involves IkBa, cellular phosphorylation and degradation of IkBa upon LPS stimulation and rCC16 pretreatment were determined by immuneblot analysis. We found that LPS exposure resulted in increased phosphorylation of IkBa and that pretreatment of cells with rCC16 suppressed this phosphorylation at concentrations 1.0 mg/mL and above (Figure 5(a) ). In accord, the decrease in the cellular level of IkBa caused by LPS was attenuated by rCC16 pretreatment at similar concentrations ( Figure 5(b) ). These results indicate that rCC16 treatment of the RTE cells also prevents LPS-induced phosphorylation and degradation of IkBa and subsequent activation of NF-kB.
rCC16 inhibits LPS-induced phosphorylation of NF-iB/ p65 and p38 MAPK
Since NF-kB activation is regulated by either its translocation-or phosphorylation-dependent pathways, 30, 34 we also Figure 6(a) , LPS increased the phosphorylation of p65 at ser276, pretreatment of cells with rCC16 suppressed this phosphorylation in a concentration-dependent manner without affecting the total levels of p65. It has been reported that the phosphorylation of p65 at Ser276 is associated with p38 MAPK signaling pathways. 35 We therefore investigated whether the inhibition of inflammatory response by rCC16 also involves p38 MAPK. As shown in Figure 6 (b), LPS (0.1 mg/mL) significantly increased the level of p-p38 compared to untreated controls, and this LPS-induced p-p38 increase was reduced by rCC16 at concentrations 1.0 mg/ mL and above. These findings indicate that rCC16 suppression of LPS-induced NF-kB activation is associated with NF-kB phosphorylation and p38 MAPK signaling pathways. Figure 5 rCC16 inhibits LPS-induced phosphorylation and degradation of IkBa in RTE cells. RTE cells were treated with rCC16 at indicated concentrations for 2 h prior LPS exposure at 0.1 mg/mL for another 1 h. Total proteins were extracted and the levels of phosphorylated IkBa (a) and IkBa (b) relative to b-actin were detected by Western blotting. One representative of three independent experiments is shown. Data are presented as the mean AE SD (n ¼ 3) of three independent experiments. **p < 0.01 indicates significant difference between groups as shown Figure 6 rCC16 inhibits LPS-induced phosphorylation of NF-kB/p65 and p38 MAPK. RTE cells were treated with rCC16 at indicated concentrations for 2 h prior LPS exposure at 0.1 mg/mL for another 1 h. Total proteins were extracted, and the levels of phosphorylated p65 (a) and p38 MAPK (b) were detected by Western blotting. One representative of three independent experiments is shown. Data are presented as the mean AE SD (n 
Uptake of rCC16 into RTE cells depends on clathrin-mediated endocytosis
Endocytosis is known to be involved in a variety of cellular processes 36 and is either mediated by clathrin-coated pits or by clathrin-independent mechanisms. Clathrin is a coat protein which is involved in forming specific endocytotic vesicles and mediates the internalization of a wide range of small molecules. 37 To determine whether clathrin-mediated endocytosis is involved in rCC16 signaling, we tested chlorpromazine, a drug that prevents formation of clathrincoated pits at the plasma membrane, 38 on the uptake of rCC16 by RTE cells. As illustrated in Figure 7(a) , RTE cells preincubated with chlorpromazine at 30 mM for 30 min displayed strong resistance against endocytosis of rCC16 (His-tagged) as shown by immunofluorescence staining with anti-His antibodies. To further confirm the importance of clathrin in the cellular uptake of rCC16, we determined the effect of chlorpromazine on nuclear translocation of NF-kB/p65 in rCC16-exposed and LPS-stimulated RTE cells using immunoblot analysis and immunofluorescence staining with the NF-kB/p65 antibody. Pretreatment of RTE cells with chlorpromazine (30 mM, 30 min) significantly blocked the inhibitory roles of rCC16 on LPS-induced NF-kB/p65 nuclear translocation (Figure 7(b) ). In accord, chlorpromazine rescued the nuclear NF-kB/p65 distribution in presence of rCC16 and LPS (Figure 7(c) ). While rCC16 was found to inhibit the translocation of NF-kB/p65 into nucleus in the presence of LPS, chlorpromazine significantly blocked the inhibitory effects of rCC16 and restored the nuclear distribution of NF-kB/p65 (Figure 7(d) ). When the levels of MMP-9 in these cells were determined using ELISA analysis, increased MMP-9 productions were visualized from chlorpromazine-pretreated RTE cells which were exposed to rCC16 and LPS, suggesting that chlorpromazine abolished the inhibitory effect of rCC16 on LPS-stimulated expression of MMP-9 (Figure 7(e) ). Taken together, these data demonstrate that clathrin-mediated endocytosis of rCC16 is critical for its inhibitory role in LPS-induced MMP-9 production during inflammatory responses.
Discussion
Our studies show that rCC16 suppresses LPS-induced MMP-9 expression in RTE cells, and that this effect involves NF-kB activation through phosphorylation and degradation of its inhibitor IkBa and the p38 MAPK signaling pathways. The inhibitory effects of rCC16 were abolished by blocking clathrin-mediated endocytosis. These data indicate that clathrin-mediated cellular uptake of rCC16 inhibits activation of NF-kB and MMP-9 expression during LPS-induced inflammatory responses in epithelial cells of the airways.
CC16 is a secretory protein with anti-inflammatory and immunomodulatory characteristics. 39 A decreased level of CC16 found in the bronchoalveolar lavage fluid of lungs is thought to be the contributing factor to airway inflammations. [40] [41] [42] [43] In animal model studies, CC16 knockout-mice express exaggerated eosinophilic inflammation during allergen challenge in their lungs. 44 These studies indicate that reduced CC16 anti-inflammatory action may contribute to the induction and development of airway inflammatory diseases. To prove a role of CC16 in antiinflammation, we generated rCC16 20 and determined its bioactivities in cultured RTE cells. We verified that our rCC16 preparations being biologically active to suppress PLA 2 activities 26, 27 at concentrations (from 0.5 to 2.0 mg/mL) without causing the RTE cells to proliferate or die (Figure 1 ).
MMP-9 generated within the lung environment regulates many physiological processes during infection, inflammation, and subsequent tissue repairs. Elevated levels of MMP-9 have been established in COPD during the development of chronic inflammation 45, 46 and are used as a distal biomarker for inflammation. 31, 47 Innate immune cells including macrophages and neutrophils are the major source of MMP-9. 14, 48 Infected bronchial epithelial cells also release MMP-9 in COPD patients. 49 In accord, LPS induces expression of MMP 19 and exacerbations of COPD. 50, 51 In A549 lung epithelial cell cultures, LPS induces MMP-9 expression through the NF-kB pathway at 0.1 mg/mL concentration. 29 We therefore employed LPS at this concentration to determine its effect on MMP-9 expression in RTE cells and the effectiveness of rCC16 as an antiinflammative in vitro. Our data suggest that LPS indeed promoted MMP-9 expression at both mRNA and protein levels in RTE cells, and that this effect was suppressed by rCC16 in a dose-dependent manner (Figure 2 ) at concentrations compatible to those detected in vivo, 43 suggesting the physiological significance of our rCC16 proteins.
NF-kB is one of the key transcription factors activated by LPS, and it has been implicated in regulating genes of the inflammatory cascade. 30 Activation of the NF-kB pathway is also associated with airway inflammation such as COPD, and suppression of this pathway has been shown to attenuate airway inflammations. 52, 53 On the other hand, the promoter of MMP-9 gene contains a highly conserved motif that matches the NF-kB p65 binding element, and inhibition of NF-kB blocks MMP-9 up-regulation. 54 Here we show that level of MMP-9 in LPS-treated RTE cells was significantly reduced by the NF-kB inhibitor PDTC (supplemental Figure 3 ), suggesting a direct role of NF-kB pathway in MMP-9 expression. To explore the molecular mechanisms of rCC16 inhibition of LPS-induced MMP-9 expression, we examined the effect of rCC16 on LPS-induced NF-kB activation by using reporter gene assays and EMSA analysis. Our results showed that LPS could induce transcriptional activation of NF-kB and this effect was suppressed together with the formation of NF-kB-DNA complexes by rCC16 in a concentration-dependent manner (Figure 3) . These data together indicate that rCC16 can inhibit LPS-induced NF-kB activation and its binding of gene promoters.
Next, we performed Western blotting analysis to determine whether rCC16 can block NF-kB activation through interruption of its signaling pathways. Both NF-kB translocation-dependent 55, 56 and NF-kB phosphorylation-dependent 33 pathways have been implicated in the activation of NF-kB. It is well established that the subunit p50/p65 complex of NF-kB is generally sequestered by its inhibitor IkBa in the cytosol. 57 Upon stimulation, IkBa is phosphorylated, ubiquitinated, and degraded to release NF-kB/p65 which (a) Chlorpromazine impedes uptake of rCC16 via clathrin-mediated endocytosis. RTE cells preincubated with chlorpromazine (30 mM; 30 min) or vehicles were exposed to rCC16 (2.0 mg/mL; 30 min) or PBS controls, immune-labeled with a mouse anti-His antibody for His-tagged rCC16 (red), and exposed to DAPI for nuclei (blue). Scale bar, 25 mm. (b, c) Chlorpromazine restores NF-kB nuclear translocation in rCC16treated RTE cells. RTE cells treated as described in (a) were exposed to LPS at 0.1 mg/mL for 1 h and cytoplasmic and nuclear distributions of NF-kB/p65 were determined by Western blotting together with b-actin and Histone H1 as internal controls, respectively. The absence of detectable b-actin in the nucleus fraction indicated the absence of nuclear protein contaminations from the cytosolic fractions. Note the chlorpromazine blockage of rCC16 inhibitory effect on LPS-induced nuclear translocation of NF-kB/p65. (d) Immunofluorescence images show the subcellular distributions of NF-kB/p65 (green) with DAPI nuclear staining (blue) in RTE cells treated with or without LPS, rCC16, and chlorpromazine. Scale bar, 100 mm. (e) Chlorpromazine promotes release of MMP-9 in rCC16-treated RTE cells. Cell culture media collected from RTE cells as described in (b) were assessed for MMP-9 levels by ELISA assays. Note the chlorpromazine blockage of rCC16 inhibitory effect on LPS-stimulated MMP-9 secretion. All data are presented as the mean AE SD (n ¼ 3) of three independent experiments. **p < 0.01 indicates significant difference between groups as shown. (A color version of this figure is available in the online journal.) Pang et al. CC16 inhibits LPS-induced MMP-9 expression via NF-kB pathway 1275 then translocates to the nucleus to activate target genes. In addition, transcriptional activity of nuclear NF-kB is also regulated by post-translational modifications, 58 for instance, phosphorylation of its p65 subunit at Ser276 59, 60 through the p38-MAPK signaling pathways. 61 Here we have demonstrated that rCC16 inhibits LPS-induced phosphorylation and degradation of IkBa ( Figure 5 ), and translocation of NF-kB/p65 subunit from the cytosol into the nuclear fractions without affecting its total protein levels (Figure 4(a) ). There is evidence that LPS induces the phosphorylation of p38 MAPK, 62 and that p38 MAPK activates NF-kB via phosphorylation of its p65 subunit at Ser276 during mitogen-and stress-activated protein kinases (MSKs) activations. 63 Additionally, LPS has been shown to phosphorylate NF-kB p65 at Ser276 64,65 which in turn regulates the transcriptional activity of NF-kB. 66, 67 In line with these reports, we found that rCC16 inhibits LPS-induced phosphorylation of p65 subunit of NF-kB at Ser276 (Figure 6(a) ), and that LPS-induced phosphorylation of p38 MAPK was markedly suppressed by rCC16 pretreatment in a concentration-dependent manner ( Figure 6(b) ).
Our observation that CC16 attenuates LPS-induced NF-kB activation through inhibiting IkBa phosphorylation and nucleus translocation of NF-kB would suggest that the translocation-dependent pathway plays a leading role in the RTE cells. This is consistent with the notion of this pathway as the first step for NF-kB signaling. 33 Our findings that rCC16 also inhibits LPS-induced phosphorylation of p38 MAPK and p65 subunit of NF-kB at Ser276 (Figure 6(a) ) indicate that the p38 MAPK-dependent pathway is also operational in RTE cells. It appears that the two pathways work sequentially in facilitating transcriptional activities of NF-kB but our data here could not differentiate the pathways as both were inhibited by rCC16. There is no interaction between p65 and CC16 found in a previous study which attempted to define CC16-interacting proteins in NF-kB pathways. 68 Similarly, it is unclear if there is an upstream site that CC16 could impact. Nevertheless, our findings together suggest that rCC16 suppresses LPSinduced NF-kB activation by down-regulating both of its translocation-and phosphorylation-dependent pathways in RTE cells.
CC16 is synthesized primarily by non-ciliated bronchiolar epithelial cells, i.e. the Clara cells. It passively diffuses into plasma across the bronchoalveolar-blood barrier from the airways. 69 In accord, no endogenous expression of CC16 proteins was detected in the RTE cells in this study (supplemental Figure 2) . To explore the route of rCC16 entry to RTE cells, we used chlorpromazine to block the formation of clathrin-coated pits at the plasma membrane in clathrin-mediated endocytosis. Our immunofluorescence staining assay showed that chlorpromazine inhibited the uptake of rCC16 by RTE cells (Figure 7(a) ). Further Western blotting and ELISA analysis confirmed that chlorpromazine blockage of cellular rCC16 uptake significantly abolished rCC16 inhibition of LPS-induced nuclear translocation of NF-kB/p65 and down-stream MMP-9 expression (Figure 7(b) , (c), and (e)). These findings suggest that rCC16 functions to inhibit MMP-9 expression in RTE cells through clathrin-mediated endocytosis.
Induction of CC16 expression by gene transfection has been shown to inhibit IL-1b induced IL-8 expression in bronchial epithelial BEAS-2B cells by suppressing the phosphorylation of IkBa and the transcriptional activity of NF-kB. 68 Our new observation was that rCC16 suppresses MMP-9 expression in LPS-stimulated RTE cells via clathrin-mediated endocytosis and inactivates both NF-kB and p38 MAPK-dependent signaling pathways. Although CC16 from different sources was used in these two studies, they all revealed the same mechanism that NF-kB pathway is involved in CC16's anti-inflammation role.
Studies currently under way in our laboratory are investigating the possible role of rCC16 in different cells of inflammatory association, including human airway epithelial cells. Further studies on the role of CC16 in airway inflammatory diseases and applications of rCC16 to its cellular and animal models could lead to the development of novel therapeutic strategies in the management of COPDlike disorders.
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